ES2154661T3 - Preparados liquidos que contienen cyclosporin y procedimiento para su obtencion. - Google Patents

Preparados liquidos que contienen cyclosporin y procedimiento para su obtencion.

Info

Publication number
ES2154661T3
ES2154661T3 ES94117612T ES94117612T ES2154661T3 ES 2154661 T3 ES2154661 T3 ES 2154661T3 ES 94117612 T ES94117612 T ES 94117612T ES 94117612 T ES94117612 T ES 94117612T ES 2154661 T3 ES2154661 T3 ES 2154661T3
Authority
ES
Spain
Prior art keywords
procedure
preparations
liquid preparations
obtaining
preparations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94117612T
Other languages
English (en)
Inventor
Hatto Dr Walch
Monika Dr Fleck
Klaus Neuer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2154661T3 publication Critical patent/ES2154661T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A PREPARACIONES LIQUIDAS, QUE CONTIENEN CICLOSPORINA PARA TRATAMIENTO ORAL O PARENTERAL ASI COMO UN PROCEDIMIENTO PARA SU ELABORACION. ESTAS PREPARACIONES CONTIENEN JUNTO A LA CICLOSPORINA COMO SUSTANCIA ACTIVA UN POLIOXIETILENO GLICERINA HOLES MONO Y/O POLIVALENTES. LAS PREPARACIONES DISPUESTAS DE FORMA CONJUNTA SON ESTABLES, CON BUENA TOLERABILIDAD Y POSEEN UNA BIODISPONIBILIDAD MEJORADA EN COMPARACION CON LOS PREPARADOS CONOCIDOS HASTA AHORA.
ES94117612T 1993-11-30 1994-11-08 Preparados liquidos que contienen cyclosporin y procedimiento para su obtencion. Expired - Lifetime ES2154661T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4340781A DE4340781C3 (de) 1993-11-30 1993-11-30 Cyclosporin enthaltende flüssige Zubereitungen und Verfahren zu ihrer Herstellung
US08/347,289 US5614491A (en) 1993-11-30 1994-11-30 Liquid preparations containing cyclosporin and process for preparing same

Publications (1)

Publication Number Publication Date
ES2154661T3 true ES2154661T3 (es) 2001-04-16

Family

ID=25931649

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94117612T Expired - Lifetime ES2154661T3 (es) 1993-11-30 1994-11-08 Preparados liquidos que contienen cyclosporin y procedimiento para su obtencion.

Country Status (16)

Country Link
US (1) US5614491A (es)
EP (1) EP0656212B1 (es)
JP (1) JP4073503B2 (es)
AT (1) ATE198833T1 (es)
CA (1) CA2137025A1 (es)
CY (1) CY2285B1 (es)
CZ (1) CZ289316B6 (es)
DE (2) DE4340781C3 (es)
DK (1) DK0656212T3 (es)
ES (1) ES2154661T3 (es)
FI (1) FI111908B (es)
GR (1) GR3035536T3 (es)
HU (1) HU218934B (es)
NO (1) NO315932B1 (es)
PT (1) PT656212E (es)
SK (1) SK282732B6 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE789561T1 (de) * 1995-08-25 1999-06-10 Sangstat Medical Corp., Menlo Park, Calif. Orale cyclosporinformulierungen
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
PT988046E (pt) * 1997-01-30 2004-12-31 Novartis Ag Composicoes farmaceuticas sem oleo contendo ciclosporina a
HU228855B1 (en) * 1997-03-12 2013-06-28 Abbott Lab Hydrophilic binary systems for the administration of cyclosporine
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
EE200100155A (et) 1998-09-17 2002-08-15 Bristol-Myers Squibb Company Ateroskleroosi ravimeetod, kasutades aP2 inhibiitorit ja selle kombinatsiooni
IL143604A0 (en) 1998-12-30 2002-04-21 Dexcel Ltd Dispersable concentrate for the delivery of cyclosporin
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7402559B2 (en) * 1999-03-24 2008-07-22 Msh Pharma, Incorporated Composition and method of treatment for urogenital conditions
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7919113B2 (en) * 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1377237B1 (en) * 2001-01-25 2008-02-27 Smith & Nephew, Inc. Containment system for constraining a prosthetic component
MXPA04005783A (es) * 2001-12-14 2004-09-13 Jagotec Ag Formulacion farmaceutica que comprende ciclosporina y uso de la misma.
JP5000848B2 (ja) 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
TW200409644A (en) * 2002-12-04 2004-06-16 Bio Max Inc Improved carrier system for cyclosporin pharmaceutical compositions
US7842791B2 (en) * 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
BRPI0514408B8 (pt) * 2004-08-24 2021-05-25 Asubio Pharma Co Ltd preparação liquida de peptídeo fisiologicamente ativo
US7276476B2 (en) * 2005-07-13 2007-10-02 Allergan, Inc. Cyclosporin compositions
US7297679B2 (en) * 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7202209B2 (en) 2005-07-13 2007-04-10 Allergan, Inc. Cyclosporin compositions
US20070015693A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) * 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US7745400B2 (en) * 2005-10-14 2010-06-29 Gregg Feinerman Prevention and treatment of ocular side effects with a cyclosporin
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
TW200932240A (en) * 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
US8861813B2 (en) * 2008-03-13 2014-10-14 Mallinckrodt Llc Multi-function, foot-activated controller for imaging system
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US20160143970A1 (en) * 2013-06-03 2016-05-26 Genyous Biomed International Novel formulations of botanical extracts for cancer therapy
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
EP3824296B1 (en) 2018-07-20 2026-04-01 Lipocine Inc. Oral pharmaceutical composition comprising testosterone tridecanoate and/or testosterone dodecanoate for treating liver diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
CH641356A5 (en) * 1979-02-27 1984-02-29 Sandoz Ag Pharmaceutical compositions containing cyclosporin
GB8903804D0 (en) * 1989-02-20 1989-04-05 Sandoz Ltd Improvements in or relating to organic compounds
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
BE1003009A5 (fr) * 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.
HU208491B (en) * 1990-11-27 1993-11-29 Gyogyszerkutato Intezet Process for producing oral pharmaceutical composition containing cyclosporin
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
DE4230876A1 (de) * 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
DK0589843T3 (da) * 1992-09-25 2002-04-02 Novartis Ag Cyclosporinholdige farmaceutiske præparater

Also Published As

Publication number Publication date
EP0656212B1 (de) 2001-01-24
SK142394A3 (en) 1995-06-07
DK0656212T3 (da) 2001-04-09
HUT68795A (en) 1995-07-28
FI945619A0 (fi) 1994-11-29
DE4340781C2 (de) 1995-11-09
FI111908B (fi) 2003-10-15
CY2285B1 (en) 2003-07-04
GR3035536T3 (en) 2001-06-29
JP4073503B2 (ja) 2008-04-09
JPH07252162A (ja) 1995-10-03
NO315932B1 (no) 2003-11-17
ATE198833T1 (de) 2001-02-15
PT656212E (pt) 2001-06-29
US5614491A (en) 1997-03-25
CZ287694A3 (en) 1995-07-12
HU9403420D0 (en) 1995-02-28
NO944567D0 (no) 1994-11-29
DE4340781A1 (de) 1995-06-01
CZ289316B6 (cs) 2002-01-16
CA2137025A1 (en) 1995-05-31
DE4340781C3 (de) 2000-01-27
NO944567L (no) 1995-05-31
SK282732B6 (sk) 2002-11-06
FI945619L (fi) 1995-05-31
DE59409644D1 (de) 2001-03-01
HU218934B (hu) 2001-01-29
EP0656212A1 (de) 1995-06-07

Similar Documents

Publication Publication Date Title
PY950041A (es) Compuesto de 1- fenil 3-dimetilamino- propano a procedimientos para su preparacion y a la aplicacion de estas sustancias en farmacologia
PT927150E (pt) Compostos de lipoxina e sua utilizacao no tratamento de doencas proliferativas celulares
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
ATE554750T1 (de) Hydrophobe pharmazeutische wirkstoffe enthaltende zubereitungen
SE9704546D0 (sv) Novel compounds
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
DK0993831T3 (da) Forbindelser og præparater til tilförsel af aktive stoffer
DE69905170T2 (de) Thiazolopyrimidinderivate
TR200401638T2 (tr) Bir reseptöre bağlanan peptidler ve bileşikler.
DK1036058T3 (da) Adamantanderivater
DE69808130D1 (de) Adamantan-derivate
ES2138271T3 (es) Compuestos de 6-dimetil-amino-metil-1-fenil-ciclohexano como principio activo farmaceutico.
DK0600866T3 (da) Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
UY26321A1 (es) Formas de administracion de tramadol retardadas mediante un revestimiento que contiene la sustancia activa tramadol en forma de sacarinato de tramadol asi como eventualmente otros excipientes
ES2097878T3 (es) Fijacion de p53 sobre el adn mediante una secuencia especifica.
EA199800946A1 (ru) Концентрированный препарат антител
GB9818916D0 (en) Use
TR200100054T2 (tr) Paroksetin metansülfonat
IL146125A0 (en) Novel quinones as disease therapies
TR199901104T2 (xx) Farmas�tik bile�ikler.
DE69840415D1 (de) Haemasterlin analoge
SE9802937D0 (sv) Novel compounds
ES2145075T3 (es) Nuevos derivados fibrinoliticos de la uroquinasa, plasmidos para su preparacion y tromboliticos que los contienen.
NO20005548L (no) Mykobakterieinhibitorer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 656212

Country of ref document: ES